Core Viewpoint - The Hong Kong Innovative Drug ETF managed by Penghua experienced a decline of 2.71% on October 30, with a trading volume of 654.934 million yuan, indicating a challenging market environment for innovative drug investments [1] Group 1: Fund Performance - The fund's latest net asset value is calculated at 588 million yuan [1] - Since its inception on August 20, 2025, the fund has reported a return of -13.59% [1] - Over the past month, the fund's return has been -14.59% [1] Group 2: Fund Activity - The fund's shares increased by 11 million shares on the same day, bringing the total shares to 681 million [1] - In the last 20 trading days, the fund's shares have increased by 136 million shares [1] Group 3: Benchmark and Management - The performance benchmark for the fund is the National Index of Hong Kong Innovative Drugs, adjusted for exchange rates [1] - The fund is managed by Penghua Fund Management Co., Ltd., with fund managers Lin Song and Zhang Yuxiang [1]
10月30日港股创新药ETF鹏华（159286）份额增加1100.00万份
Xin Lang Cai Jing·2025-10-31 01:11